NEW YORK (GenomeWeb News) – Health Canada has issued a license to SQI Diagnostics allowing the company to market its multiplexed Ig_plex Celiac DGP Panel, the Toronto-based firm said today.

The panel is intended for use in clinical laboratories to help diagnose celiac disease and provides semi-quantitative determination of the IgG and IgA immunoglobulin classes of deamidated gliadin peptide and anti-tissue transglutaminase antibodies in a single test that requires only one human sample, SQI said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.